Auryon uses atherectomy laser technology for treating peripheral arterial disease (PAD). Vascular blockage of the lower extremities is the main cause of 66% of limb amputations in the United States (approximately 120,000 amputations per year).
Peripheral laser atherectomy uses a catheter that emits high-energy light (laser) to unblock the artery. The catheter is maneuvered through the vessel until it reaches the blockage and then laser energy is used to essentially vaporize the blockage inside the vessel.
The result is increased blood flow to the peripheral tissue. Auryon’s technology is unique due to its high level of adaptability to different medical situations, its precision, which helps to protect the vessel wall, and its high efficiency.
Eximo, a company that started working with Taga as a
... read moreAuryon uses atherectomy laser technology for treating peripheral arterial disease (PAD). Vascular blockage of the lower extremities is the main cause of 66% of limb amputations in the United States (approximately 120,000 amputations per year).
Peripheral laser atherectomy uses a catheter that emits high-energy light (laser) to unblock the artery. The catheter is maneuvered through the vessel until it reaches the blockage and then laser energy is used to essentially vaporize the blockage inside the vessel.
The result is increased blood flow to the peripheral tissue. Auryon’s technology is unique due to its high level of adaptability to different medical situations, its precision, which helps to protect the vessel wall, and its high efficiency.
Eximo, a company that started working with Taga as a small start-up coming out from a technological incubator, came to us with an idea and an Alpha feasibility model.
Before setting out, we conducted in-depth market research, analyzing the competitors’ products and the medical situation. We tried to understand how to make their technology function within a complex medical situation.
Next, we took the company throughout all the lifecycle of a medical product: design, development, UX/UI design, and manufacturing. As part of the process we helped the company to get into clinical trials with humans and assisted in the FDA approval process in an early stage, as usual, it is a long and complex procedure.
Then we helped Eximo to get into production and produced for their prototypes, tooling of large injection molds, and serial production of the large system parts.
As a result of the company’s quick moves and Taga’s extensive support, Eximo was acquired by AngioDynamics for $66 Million, in one of the fastest exits in the industry.
read less
Bringing new improved laser technology to treat peripheral arterial disease.
Following the company’s fast development of its technology and Taga’s extensive support in design, development and production, Eximo was acquired by AngioDynamics for $66 Million, within 7 years from initiation.
